Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)

被引：5
|
作者：
Nowak, A. K. [1 ]
Millward, M. J. [1 ]
Francis, R. [1 ]
van der Schaaf, A. [1 ]
Musk, A. W. [1 ]
Byrne, M. J. [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8063
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Second-Line Chemotherapy for Malignant Pleural Mesothelioma (MPM): Patterns of Care in Two Australian Tertiary Institutions
    Palmieri, David
    Hui, Rina
    Kao, Steven
    Boyer, Michael
    Park, John
    Nagrial, Adnan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 134 - 134
  • [22] Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
    Pagano, Maria
    Ceresoli, Luca Giovanni
    Zucali, Paolo Andrea
    Pasello, Giulia
    Garassino, Marina
    Grosso, Federica
    Tiseo, Marcello
    Soto Parra, Hector
    Zanelli, Francesca
    Cappuzzo, Federico
    Grossi, Francesco
    De Marinis, Filippo
    Pedrazzoli, Paolo
    Gnoni, Roberta
    Bonelli, Candida
    Torricelli, Federica
    Ciarrocchi, Alessia
    Normanno, Nicola
    Pinto, Carmine
    CANCERS, 2020, 12 (10) : 1 - 12
  • [23] Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
    Vincenzo Di Noia
    Emanuele Vita
    Miriam Ferrara
    Antonia Strippoli
    Michele Basso
    Giovanni Schinzari
    Alessandra Cassano
    Emilio Bria
    Carlo Barone
    Ettore D’Argento
    Current Treatment Options in Oncology, 2019, 20
  • [24] Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"
    Di Noia, Vincenzo
    Vita, Emanuele
    Ferrara, Miriam
    Strippoli, Antonia
    Basso, Michele
    Schinzari, Giovanni
    Cassano, Alessandra
    Bria, Emilio
    Barone, Carlo
    D'Argento, Ettore
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (03)
  • [25] Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study
    Pagano, M.
    Gnoni, R.
    Bonelli, C.
    Zanelli, F.
    Garassino, M. C.
    Ceresoli, G. L.
    Pasello, G.
    Tiseo, M.
    Parra, H. J. Soto
    Grosso, F.
    Zucali, P. A.
    Larocca, M.
    Torricelli, F.
    Ciarrocchi, A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
    Fennell, Dean A.
    McDowell, Cliona
    Busacca, Sara
    Webb, Glen
    Moulton, Brian
    Cakana, Andrew
    O'Byrne, Kenneth J.
    Meerbeeck, Jan V.
    Donnellan, Paul
    McCaffrey, John
    Baas, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1466 - 1470
  • [27] A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)
    Zucali, P. A.
    Ceresoli, G. L.
    Favaretto, A. G.
    Cortinovis, D.
    Grossi, F.
    Marangolo, M.
    Del Conte, G.
    Ceribelli, A.
    Bearz, A.
    Parra, H. Soto
    Santoro, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 28 - 28
  • [28] Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a phase II study
    Talbot, D
    Margery, J
    Dabouis, G
    Dark, G
    Taylor, H
    Macha, H
    Pinel, M
    Betton, A
    Riviere, A
    Ruffie, J
    LUNG CANCER, 2005, 49 : S230 - S230
  • [29] A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)
    Parra, HS
    Zucali, R
    Favaretto, A
    Grossi, F
    Fusi, A
    Marangolo, M
    Del Conte, G
    Ceribelli, A
    Bearz, A
    Ceresoli, G
    LUNG CANCER, 2005, 49 : S229 - S229
  • [30] A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).
    Wozniak, Antoinette J.
    Schneider, Bryan J.
    Kalemkerian, Gregory Peter
    Daly, Robert Michael
    Chen, Wei
    Ventimiglia, Jaclyn
    Nagasaka, Misako
    Zauderer, Marjorie Glass
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345